ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform

S. Berger1, M. Bakr1, F. Bemelman1, R. Danguilan1, H. De Fijter1, D. Han1, M. Kim1, E. Mor1, A. Patel1, M. Hernandez Gutierrez2, A. Gawai2, Y. Watarai1

1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland

Meeting: 2020 American Transplant Congress

Abstract number: D-036

Keywords: Efficacy, Immunosuppression, Living donor, Safety

Session Information

Session Name: Poster Session D: Kidney Living Donor: Long Term Outcomes

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: To assess the efficacy and safety outcomes in de novo renal transplant (RTx) recipients receiving everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI) versus mycophenolate with standard-exposure CNI (MPA+sCNI) by donor type (living donor [LD] versus deceased donor [DD]) in TRANSFORM (NCT01950819) study.

*Methods: In this 24-month (M), Phase 4, multicenter, open-label study, 2037 adult patients were randomized to receive EVR+rCNI or MPA+sCNI with steroids and basiliximab or rabbit antithymocyte globulin as induction therapy. Efficacy assessments were incidence of binary composite of treated biopsy-proven acute rejection (tBPAR) or estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m2, incidence tBPAR, graft loss, or death, and evolution of eGFR up to M24; safety assessments were incidence of adverse events (AEs) and infections.

*Results: In all, 1018 and 1011 patients received allografts from LD and DD, respectively. Demographics and baseline characteristics were similar between the treatment arms of both donor groups. Incidence of binary composite endpoint was comparable between EVR+rCNI and MPA+sCNI regimens in both donor groups (LD: P = 0.242; DD: P = 0.145) at M24. Regardless of the donor types, incidence of tBPAR, graft loss, and death were comparable between the treatment arms. Compared with patients in the DD group, mean eGFR was numerically higher in both treatment arms of the LD group (Table). Overall incidence of infections was numerically lower in the EVR+rCNI arm versus MPA+sCNI arm of both donor groups.

*Conclusions: Irrespective of donor type, EVR+rCNI regimen offers comparable efficacy and safety and stable renal function as MPA+sCNI regimen up to M24 post-transplant.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Berger S, Bakr M, Bemelman F, Danguilan R, Fijter HDe, Han D, Kim M, Mor E, Patel A, Gutierrez MHernandez, Gawai A, Watarai Y. Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/efficacy-and-safety-outcomes-by-donor-type-in-de-novo-renal-transplant-recipients-receiving-everolimus-with-reduced-dose-calcineurin-inhibitor-24-month-results-from-transform/. Accessed May 9, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences